Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1851 results
March 2019
-
Story Discovery
Visualizing immuno-oncology research
Learn how Novartis researchers are working to outsmart tumors.
-
Press release
Alcon Announces Acquisition of PowerVision, Inc.
Acquisition demonstrates Alcon's commitment to driving growth and innovation in advanced technology intraocular lenses (AT-IOLS) to meet the needs of cataract surgery patients who desire… -
Press release
Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy
Study is planned to assess efficacy and safety of Entresto® (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019… -
Featured News
Global Equal Parental Leave Policy for all Novartis parents
Fourteen weeks. That’s how many weeks all new Novartis parents will get as minimum paid parental leave, regardless of gender, rolling out from July 1, 2019.
-
Ad hoc release
Novartis announces change in Sandoz leadership
Richard Francis, CEO Sandoz, to step down on March 31, 2019 Francesco Balestrieri, Head Region Europe, Sandoz, appointed ad-interim CEO Sandoz Basel, March 14, 2019 - Novartis announced… -
Press release
Three winners of 2019 Sandoz Healthcare Access Challenge (HACk) are announced at SXSW
Sandoz commits to increasing support from one winner to three, following impressive pitches from the finalists Winning ideas proposed innovative uses of artificial intelligence, mobile apps and… -
Story People and Culture
Enabling 130,000 employees to grow in an organization committed to continuous learning
Our Chief Learning Officer, Simon Brown, talks about our ongoing efforts to build new capabilities by investing in our own people.
-
Press release
Novartis Cosentyx® shows superior improvements in psoriasis patients' quality of life versus Janssen's IL-23 Stelara®*
New CLARITY data show over two-thirds of Cosentyx (secukinumab) treated patients with moderate to severe psoriasis reported no impact of skin disease on their quality of life (QoL) up to Week 16… -
Press release
Novartis data confirm rapid response and high efficacy of Cosentyx® in psoriasis patients for first time in China
Phase III study shows close to 9/10 patients who received Cosentyx® 300mg achieved clear or almost clear skin during the first 16 weeks of treatment (87%), with rapid onset of relief seen as early… -
Story Access to Healthcare
Novartis Access impact evaluation: progress update on our work with Boston University
Boston University developed a methodology to evaluate the impact of Novartis Access in Kenya. Peter C. Rockers tells us about the ongoing study.
February 2019
-
Press release
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
Shareholders approve 22nd consecutive dividend increase to CHF 2.85 (+2%) per share for 2018; representing a 3.1% yield and approximately 57% payout of free cash flow Overwhelming majority of… -
Press release
Die Aktionäre von Novartis heissen an der Generalversammlung alle Anträge des Verwaltungsrates gut
Die Aktionäre bewilligen die 22. Dividendenerhöhung in Folge. Für 2018 wird die Dividende auf CHF 2.85 (+2%) je Aktie erhöht, was einer Rendite von 3,1% und einem Anteil von etwa 57% des freien…